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New Concept of Medicines
Nowadays, medicine is no longer for clinical diseases 
only. The paradigm of medicine has changed from 
disease to healthcare. The scope of medicine includes 
uses for disease treatment (therapeutic medicine), 
disease prevention (preventative medicine), life quality 
enhancement of patients and healthy individuals 
(functional medicine), and for improving the use of 
other medicines (accessory medicine).
The current paradigm of mainstream pharmaceutical 
discovery uses a reductionist approach to identify a 
target associated with disease or a single compound that 
can regulate a given target associated with a disease. 
Such compounds are expected to have potency and 
selectivity for the treatment of the disease targeted.
There  are  several  chal lenges  to  the  current 
mainstream drug discovery approach. A given disease 
can be caused by multiple reasons; therefore, it will 
be difficult to find one chemical with a defined target 
related to a specific disease, because the overall 
medicine helped treat a majority of the patients and 
prevented a majority from contracting the disease. Many 
potent drugs for the treatment or prevention of chronic 
diseases may require long-term use, and delayed toxicity 
may occur.
A new pharmaceutical industry, polychemical in 
nature, based on historical information from each 
geographical area, and with clinical evidence-based 
and consistent preparation, could be a focal point of 
economic development in each geographical area. 
Therefore, a new paradigm for future medicine is a 
multiple-target and polychemical medicine instead of a 
one-chemical medicine with a system-biology approach 
in mind. There are two approaches to polychemical 
medicine: conventional “step by step” and revisiting 
history as the basis of reinventing medicine.
Figure 1 indicates the FDA pathway for botanical 
drugs. Botanical products with a history of safe use may 
start efficacy studies at Phase 2 clinical trials without 
preclinical requirements. Actual new drug application 
(NDA) requirements are identical to those of new 
chemical entities (NCEs), except that the combination 
product rule is waived; therefore, it is not necessary 
to study the individual active ingredients. The FDA 
has defined special policies for meeting chemistry, 
manufacturing, and control requirements; and as you 
might expect, this is technically quite challenging. The 
drug sponsor has considerable flexibility over when 
the required toxicology and human safety studies are 
conducted; therefore, development programs may be 
compressed with a parallel execution of toxicity, safety, 
and efficacy studies, or reversed as compared to NCEs 
with safety and toxicity studies following efficacy 
Figure 1. FDA Pathway for Botanical Drugs
NCE: new chemical entity; NDA: new drug application
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studies. In PhytoCeutica’s view, the pathway has opened 
up a large pool of previously untapped drug candidates, 
many of which have both clinical and market validation, 
enabling accelerated development with a lower risk 
of attrition. PhytoCeutica’s focus is on acute disease 
markets where existing therapies do not meet patients’ 
needs (Jiang et al., 2011). 
The Unique Features of Traditional 
Chinese Medicine
Many tradit ional  medicines took a “holist ic 
approach,” which is just becoming an important area 
of medical research today. Some of these traditional 
medicines have claimed to meet those unmet clinical 
needs. Chinese herbal medicine takes a holistic 
approach, and is an early form of “system biology”-
based “integrated medicine.” Chinese medicine is 
prescribed on an individual basis to optimize its usage 
(Lu et al., 2011). It is “individualized medicine.” 
Chinese herbal medicine has multiple medical claims 
for the treatment of complicated diseases, multiple 
symptoms, disease prevention, and life quality 
improvement. Chinese herbal medicine also has many 
chemicals that could target multiple sites, or act on a 
single site additively or synergistically through direct 
or indirect interaction (Konkimalla and Efferth, 2008). 
Chinese herbal medicine could meet some of the current 
unmet medical needs. It has its own concept, and can 
serve as the basis for developing future medicine.
The Approaches for Advancing Traditional 
Chinese Medicine
The approaches for advancing traditional Chinese 
medicine are described in Figure 2.
Figure 2. Approaches for advancing traditional Chinese medicine
The basic regulatory requirements for modern 
drugs enforce consistency of preparation, evidence-
based clinical efficacy, safety, certain knowledge of a 
drug’s action, sites of actions, active ingredients, and 
interactions with other drugs.
As mentioned above, the approval of Chinese herbal 
medicine must ensure that a consistent preparation 
of clinical trial material should work. Therefore, the 
manner in which consistent preparations of herbal 
medicine can be made is important. We have to identify 
herbs using microscopic/morphological analysis, gene 
sequence analysis, and chemical analysis in vitro 
(solution state) and in situ (solid state). We also can 
use Good Agricultural Practices (GAP) and Good 
Manufacturing Practices (GMP) to guarantee the quality 
of herb. Botanical/herbal medicine quality control in 
GAP is consistent with the use of raw herbal ingredients. 
GAP monitors botanical identification, collection, 
post-harvest processing, and agriculture contaminants, 
including heavy metals, pesticides, fungicides, 
herbicides, bacteria, plant, and fungal contaminants.
Chinese herbal medicines are mixture medicines; 
therefore, the quality control for complex mixtures is 
very important. A novel approach is required; we can 
use multiple parameters and inclusive Comprehensive 
Quality Control Measures. Moreover, there are two 
tiered approaches to botanical quality control (QC). 
Tier 1 is the fingerprint analysis, which includes global 
and relative quantitation by chemical fingerprint, 
bioresponse fingerprint, and informatics/data mining 
technologies. Tier 2 is the simplified analysis, which 
includes the specific and absolute quantitation, such 
as chemicals relevant to the pharmacological activity, 
genomic pathways, and a biological analysis relevant 
to the pharmacological activity, including the impact on 
the targeted enzyme/receptor.
Clinical trials of traditional Chinese medicine must 
ensure that a consistent preparation of clinical trial 
material is possible to produce. Double blind and 
placebo design is preferable in clinical trials. Other 
alternative designs could be taken into consideration, 
such as a clear clinical endpoint that is acceptable 
worldwide and regulations for carefully monitoring 
efficacy and toxicity. Statistical consideration is also 
critical in the drug design.
The basic study of herbal medicine includes rigorous 
preclinical and clinical studies, multiplex analysis, 
and a systems biology approach, which is driven by 
information and data mining.
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Discoveries using the approaches outlined above 
for herbal medicine could facilitate the single-targeted 
orientation approach in Western Medicine.
Collaboration is Highly Required
The evolution of medicine is not only a responsibility 
for scientists but also for the botanical drug industry. 
The botanical drug industry should heed the following 
responsibilities: evidence-based therapeutic claims, 
high-level Quality Control, full documentation of 
agricultural sourcing, full use of standard operating 
procedures, attention to drug-botanical drug interactions, 
and research focuses on the mechanism of action and 
the identification of active phytochemicals.
The outcome of developing such a polychemical and 
herb-based industry will provide high-quality products 
based on traditional healthcare uses, decrease the 
cost of healthcare, provide new scientific information 
to advance future medicine, stimulate value-added 
agricultural development, and provide economic 
development with a regional flavor.
To globalize Chinese herbal medicine, collaboration 
is critical (Figure 3). Close collaboration among 
academia, industry, and government is important. Given 
the limitation of resources (human, technological, and 
financial), international collaboration is critical for this 
advancement.
Therefore, the global, non-profit, non-discriminatory, 
and non-polit ical organization Consortium for 
Globalization of Chinese Medicine (CGCM) was 
established in December 2003. The mission of CGCM 
is to advance the field of Chinese Herbal Medicine to 
benefit humankind through joint efforts with academics, 
industries, and regulatory agencies worldwide in the 
spirit of contributions and sharing.
Globalizing Chinese Medicine
In order to globalize Chinese herbal medicine, we 
need more scientific evidence. Figure 4 describes the 
evolution of medicines.
Chinese herbal medicine is a historical medicine with 
many experience-based claims; however, its defects 
are not very evidence-based. Therefore, the first step 
is to convert experience-based claims to evidence-
based claims. The use of Chinese herbal medicine is 
based on the experiences of the doctor; and the doctor 
can adjust the components of the prescription through 
her or his own experience. Therefore, Chinese herbal 
medicine should add more objective quality control to 
prescriptions. Further, the preparation of Chinese herbal 
medicine involves many procedures. Some Chinese 
herbs require complicated processing procedures 
to become Chinese herbal medicine.  All  these 
requirements indicate that Chinese herbal medicine is 
not a friendly system for general use. Because Chinese 
herbal medicine formulas usually contain more than 
one component and the components are modulated by 
doctors’ experiences, the practice differs from Western 
medicine. Chinese herbal medicine is based on a holistic 
approach; there is not enough scientific evidence to 
demonstrate safe dosage of Chinese herbs. Hence, 
Chinese medicines need more short-term and long-
term clinical trials to understand the dosage safety of 
Chinese herbal medicine. If Chinese herbal medicine 
can overcome the defects mentioned above, it could 
become a mainstream medicine or a strong support 
for mainstream medicine. Chinese herbal medicine’
s interactions with mainstream medicine also need to 
be estimated, such as whether it collaborates in a good Figure 3. Collaboration needed to globalize Chinese and herbal 
medicine
Figure 4. The evolution of medicine
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or bad way. Moreover, Chinese herbal medicine could 
use modern scientific technology to deduce its quality 
control, informatics, clinical uses, herbal resources, 
molecular mechanisms and active compounds, 
intellectual properties, education benefits, and industrial 
liaisons. We should encourage Chinese herbal medicine 
to become evidence-base medicine. If we could 
identify the resources, molecular mechanisms, etc. of 
Chinese herbal medicine, it could be a resource for new 
medicine. Overall, collaboration is a crucial point for 
Chinese herbal medicine; it could instigate a further 
evolution of medicine.
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